ArticleLeukemia2016
Familial risk of non-Hodgkin lymphoma by sex, relationship, age at diagnosis and histology: a joint study from five Nordic countries.
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.Blood · 2018Trial
- Clinical applications of gene therapy for rare diseases: A review.International journal of experimental pathology · 2023Review
- CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk.Cell death & disease · 2022Article
- Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Lymphoblastic lymphoma in two young siblings (coincidence or genetics?): two case reports.Journal of medical case reports · 2021Article
- Article
- Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer.Cancers · 2021Article
- Epidemiology of Marginal Zone Lymphoma.Annals of lymphoma · 2021Article
- Epidemiology of Follicular Lymphoma.Hematology/oncology clinics of North America · 2020Review
- Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.Blood · 2019Article
- Conjunctival lymphomas in Japanese monozygotic twins: A case report.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to estimate stratified absolute (cumulative) and relative (standardized incidence ratios; SIRs) risks of non-Hodgkin lymphoma (NHL) in relatives of NHL patients. A cohort of 169 830 first-degree relatives of 45 406 NHL patients who were diagnosed between 1955 and 2010 in five European countries was followed for cancer incidence. The lifetime (0-79 year) cumulative risk of NHL in siblings of a patient with NHL was 1.6%, which represents a 1.6-fold increased risk (SIR=1.6, 95% confidence interval (CI)=1.2-1.9) over the general population risk. NHL risk among parent-offspring pairs was increased up to 1.4-fold (95% CI=1.3-1.5; lifetime risk 1.4%). The lifetime risk was higher when NHL was diagnosed in a sister (2.5% in her brothers and 1.9% in her sisters) or a father (1.7% in his son). When there were ⩾2 NHL patients diagnosed in a family, the lifetime NHL risk for relatives was 2.1%. Depending on sex and age at diagnosis, twins had a 3.1-12.9% lifetime risk of NHL. Family history of most of the histological subtypes of NHL increased the risk of concordant and some discordant subtypes. Familial risk did not significantly change by age at diagnosis of NHL in relatives. Familial risk of NHL was not limited to early onset cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.